A phase 3 trial shows no impact of the anticoagulant rivaroxaban on the risk of cognitive decline in individuals with atrial fibrillation and low thromboembolic risk — highlighting the need for a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback